Dr Peter Szlosarek, chief and principal investigator of several clinical studies here at the Barts Cancer Centre, will this Wednesday 18th October present exciting new data at the IASLC's (International Association for the Study of Lung Cancer) 18th World Conference on Lung Cancer, Yokohama, Japan.
Highlighting plans for future clinical studies, his talk, “Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma” will focus on the synergism between the arginine-lowering agent (AID-PEG20, Polaris Pharma) and PD1/PD-L1 axis immune checkpoint blockade in ASS1 negative tumours.
These new developments follow on from the success of the first-ever randomised trial of ADI-PEG20 in mesothelioma (ADAM) that reported an improvement in progression free survival (Szlosarek et al, Jama Onc 2017).
Tomorrow, Wednesday 18th October, Dr Peter Szlosarek will present "Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma" at the 18th IASLC World Conference on Lung Cancer, Yokohama, Japan...